Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueTax ProvisionsTax Rate
Others
Ratios

Healthstream (HSTM) Research & Development (2016 - 2025)

Historic Research & Development for Healthstream (HSTM) over the last 17 years, with Q3 2025 value amounting to $12.1 million.

  • Healthstream's Research & Development rose 5.79% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.9 million, marking a year-over-year increase of 160.16%. This contributed to the annual value of $48.9 million for FY2024, which is 735.62% up from last year.
  • As of Q3 2025, Healthstream's Research & Development stood at $12.1 million, which was up 5.79% from $12.1 million recorded in Q2 2025.
  • Healthstream's 5-year Research & Development high stood at $12.7 million for Q4 2024, and its period low was $9.5 million during Q1 2021.
  • Its 5-year average for Research & Development is $11.4 million, with a median of $11.7 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 3200.51% in 2021, then crashed by 501.05% in 2023.
  • Over the past 5 years, Healthstream's Research & Development (Quarter) stood at $11.5 million in 2021, then grew by 3.08% to $11.8 million in 2022, then rose by 1.04% to $11.9 million in 2023, then rose by 6.3% to $12.7 million in 2024, then dropped by 4.53% to $12.1 million in 2025.
  • Its Research & Development was $12.1 million in Q3 2025, compared to $12.1 million in Q2 2025 and $12.0 million in Q1 2025.